AMGEN at AHA

AHA Scientific Sessions 2021

November 13–15, 2021, Virtual

Amgen is proud to be part of the American Heart Association Scientific Sessions 2021. While you're here, you can explore the latest scientific information and disease state education from Amgen, and learn about Amgen's long-term commitment to developing and delivering transformative medicines for patients with cardiovascular disease.

VIEW AMGEN DATA PRESENTATIONS HERE

Cardiometabolic Pipeline

PROFICIO Clinical Development Program-Introducing VESALIUS-CV

PROFICIO Clinical Development Program—Introducing VESALIUS-CV

Learn about PROFICIO, Amgen’s program of clinical studies of evolocumab. Introducing VESALIUS-CV, a global initiative exploring the potential of evolocumab for the prevention of first CV events. This is an investigational study. Evolocumab is not indicated for this intended use.

DOWNLOAD BOOKLET

Please note: Some of the information on this page may pertain to investigational drugs.